Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065990 | 1.00 | MEN1 (0.55) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL2230223 | 1.00 | MEN1 (0.55) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1334464 | 0.90 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1334462 | 0.90 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL1335011 | 0.90 | HPGD (0.51) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL25513795 | 0.87 | HPGD (0.60) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL2927661 | 0.87 | HPGD (0.60) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL18549298 | 0.82 | NR1H2 (0.54) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL970631 | 0.82 | NR1H2 (0.54) | MEN1ALDH1A1MAPTKMT2AHPGD | |
| SCHEMBL12908 | 0.81 | ALDH1A1 (0.56) | MEN1ALDH1A1MAPTKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| CN-107033097-B | Oxadiazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-25 | — | — | US | disclosed |
| EP-2519235-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-11-21 | — | — | EP | disclosed |
| EP-2361248-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2018-09-19 | — | — | EP | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| EP-1875903-B1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | NABRIVA THERAPEUTICS AG (AT) | 2010-07-28 | — | — | EP | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-1875903-A1 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Nabriva Therapeutics Forschungs GmbH (AT) | 2008-01-09 | — | — | EP | disclosed |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2007-11-22 | — | — | US | disclosed |
| US-20050215637-A1 | Tuberculosis treatment | ASCHER GERD | 2005-09-29 | — | — | US | disclosed |
| US-20050131023-A1 | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2005-06-16 | — | — | US | disclosed |
| EP-1501495-A1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | Sandoz AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1492518-A2 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | Sandoz AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003090740-A1 | USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI | SANDOZ AG (CH) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003082260-A2 | TUBERCULOSIS TREATMENT USING PLEUROMUTILIN DERIVATIVES | SANDOZ AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | MEN1 606/4885ALDH1A1 684/4885MAPT 1888/4885 |
| US-20050131023-A1 | Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori | FABP6, PLEC, UBQLN2 | MEN1 626/4885ALDH1A1 979/4885MAPT 3998/4885 |
| US-20050215637-A1 | Tuberculosis treatment | TTR, TST, TREH | MEN1 1178/4885ALDH1A1 797/4885MAPT 1815/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MEN1 3174/4885ALDH1A1 2583/4885MAPT 3269/4885 |
| US-20190192512-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MEN1 606/4885ALDH1A1 684/4885MAPT 1888/4885 |
| US-20070270404-A1 | Tuberculosis treatment using pleuromutilin derivatives | PLEC, TTR, TREH | MEN1 559/4885ALDH1A1 1152/4885MAPT 2123/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MEN1 3174/4885ALDH1A1 2583/4885MAPT 3269/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | MEN1 3102/4885ALDH1A1 1989/4885MAPT 2723/4885 |
| US-20190117650-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MEN1 606/4885ALDH1A1 684/4885MAPT 1888/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MEN1 3174/4885ALDH1A1 2583/4885MAPT 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.